WVE-006

N/A

Report date: 2025/12/19 17:07:00
NME

Base Information

Drug NameWVE-006
Drug Alias NameAIMersSERPINA1 stereopure nucleic acid therapeuticWVE-006GSK-5462688
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionAlpha-1-antiproteinase modulatorsRNA modulators
TargetsAlpha-1-antiproteinaseRibonucleic Acid
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWave Life Sciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcWave Life Sciences Ltd
Inactive CompaniesN/A
Active Indicationsalpha 1-Antitrypsin Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A